DDInter548 DDInter1698
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Ertugliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) upregulates {v} (Gene) CCP110
CCP110 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Diethylstilbestrol (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) resembles Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) upregulates CCP110 (Gene) and CCP110 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diethylstilbestrol (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan